Table 2.

Kp ratios in the human brain PBPK model (with and without Pgp) versus Kp ratios from rodent studies (with and without Pgp)

Compound	Kp ratios human PBPK model	Kp ratios in rat/mouse studies
Digoxin (adult 35y)	2.7	10.0–27.8 (Mayer et al. 1997; Schinkel et al. 1995)
Digoxin (child 1mnd)	2.0	10.0–27.8 (Mayer et al. 1997; Schinkel et al. 1995)
Verapamil	2.3	5.3–30 (Bauer et al. 2012; Römermann et al. 2013; Sadiq et al. 2015)
Quinidine	2.7	4.2–27.6 (Kusuhara et al. 1997; Pussard et al. 2007)
Ivermectin	45	26.4–59.2 (Geyer et al. 2009; Kiki-Mvouaka et al. 2010; Schinkel et al. 1994)
Indinavir	4.5	9.4–21.3 (Chu et al. 2012; Kim et al. 1998)
Vincristine	4.3	1.4 (Wang et al. 2010)
Paclitaxel	1.0	2.0–7.9 (Gallo et al. 2003; Kemper et al. 2003)
Olanzapine	3.9	2.7 (Wang et al. 2004)
Citalopram	1.0	2.0–3.5 (Bundgaard et al. 2012; Uhr and Grauer 2003)

Simulations are performed in an “average” adult (35 y) or pediatric (1 mnd) individual